tiprankstipranks
Trending News
More News >

CollPlant Biotechnologies Secures $3.6 Million in Direct Offering

Story Highlights
  • CollPlant Biotechnologies announced a $3.6 million direct offering on May 30, 2025.
  • The offering aims to support CollPlant’s financial flexibility and strategic initiatives.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CollPlant Biotechnologies Secures $3.6 Million in Direct Offering

Confident Investing Starts Here:

Collplant Holdings ( (CLGN) ) has provided an update.

On May 30, 2025, CollPlant Biotechnologies announced a $3.6 million registered direct offering, issuing 1,200,002 ordinary shares at $3.00 per share. The offering, expected to close by June 2, 2025, aims to bolster the company’s financial flexibility and support its business plan, including collaborations with AbbVie and ongoing research and development initiatives. This move reflects CollPlant’s strategic efforts to enhance its market position in the regenerative and aesthetic medicine sectors.

The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

Collplant Holdings exhibits significant financial weaknesses, primarily due to a drastic revenue decline and negative cash flow. While technological advancements and strategic collaborations provide some optimism, the current financial instability remains the most significant risk. Technical analysis suggests potential overvaluation, reinforcing a cautious outlook.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products using its proprietary plant-based genetic engineering technology to produce recombinant human collagen (rhCollagen). The company’s products are designed for applications in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. CollPlant has a notable partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers.

Average Trading Volume: 57,307

Technical Sentiment Signal: Hold

Current Market Cap: $52M

For a thorough assessment of CLGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App